Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | AGER | Q15109 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355140 | 0.88 | HSD11B1 (0.50) | HSD11B1TSHRBRD4ADORA2AMEN1 | |
| SCHEMBL1354697 | 0.87 | HSD11B1 (0.54) | HSD11B1TSHRBRD4ADORA2APDK2 | |
| SCHEMBL1355477 | 0.86 | TSHR (0.53) | HSD11B1TSHRBRD4ADORA2AAGER | |
| SCHEMBL1354663 | 0.84 | TSHR (0.59) | HSD11B1TSHRBRD4ADORA2AMEN1 | |
| SCHEMBL1353254 | 0.83 | HSD11B1 (0.55) | HSD11B1TSHRBRD4ADORA2AAGER | |
| SCHEMBL1356197 | 0.82 | HSD11B1 (0.60) | HSD11B1TSHRBRD4ADORA2AAGER | |
| SCHEMBL1355447 | 0.82 | KMT2A (0.47) | HSD11B1TSHRBRD4ADORA2AMEN1 | |
| SCHEMBL1353256 | 0.81 | ADORA2A (0.55) | HSD11B1TSHRBRD4ADORA2AAGER | |
| SCHEMBL10722280 | 0.78 | HSD11B1 (0.70) | HSD11B1TSHRBRD4ADORA2AAGER | |
| SCHEMBL1354645 | 0.77 | HSD11B1 (0.53) | HSD11B1TSHRBRD4ADORA2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2391625-B1 | New adenosine receptor ligands and uses thereof | DOMAIN THERAPEUTICS (FR) | 2013-05-01 | — | — | EP | disclosed |
| EP-2391625-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | Domain Therapeutics (FR) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| WO-2010084425-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2010-07-29 | — | — | WO | disclosed |
| EP-2210891-A1 | New adenosine receptor ligands and uses thereof | Domain Therapeutics (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | ADORA2A, ADORA1, ADORA2B | HSD11B1 2224/4885TSHR 650/4885BRD4 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.